Genocea Biosciences (GNCA)

Genocea Biosciences Stock Analysis & Ratings

GNCA Stock Chart & Stats

Day’s Range$0.21 - $0.245
52-Week Range$0.16 - $2.68
Previous Close$0.23
Average Volume (3M)1.60M
Market Cap$13.50M
P/E Ratio-0.4
Next EarningsJul 28, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A
EPS (TTM)-0.53



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Genocea Biosciences’s price range in the past 12 months?
Genocea Biosciences lowest stock price was $0.16 and its highest was $2.68 in the past 12 months.
    What is Genocea Biosciences’s market cap?
    Genocea Biosciences’s market cap is $13.50M.
      What is Genocea Biosciences’s price target?
      The average price target for Genocea Biosciences is $3.54. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $0.16. The average price target represents 1441.81% Increase from the current price of $0.23.
        What do analysts say about Genocea Biosciences?
        Genocea Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Genocea Biosciences’s upcoming earnings report date?
          Genocea Biosciences’s upcoming earnings report date is Jul 28, 2022 which is in 71 days.
            How were Genocea Biosciences’s earnings last quarter?
            Genocea Biosciences released its earnings results on May 05, 2022. The company reported -$0.225 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.055.
              Is Genocea Biosciences overvalued?
              According to Wall Street analysts Genocea Biosciences’s price is currently Undervalued.
                Does Genocea Biosciences pay dividends?
                Genocea Biosciences does not currently pay dividends.
                What is Genocea Biosciences’s EPS estimate?
                Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Genocea Biosciences have?
                Genocea Biosciences has 58,780,000 shares outstanding.
                  What happened to Genocea Biosciences’s price movement after its last earnings report?
                  Genocea Biosciences reported an EPS of -$0.225 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -7.692%.
                    Which hedge fund is a major shareholder of Genocea Biosciences?
                    Currently, no hedge funds are holding shares in GNCA


                    Genocea Biosciences Stock Analysis

                    Smart Score
                    Not Ranked
                    Price Target
                    ▲(1441.81% Upside)
                    Moderate Buy
                    This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Genocea Biosciences

                    Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

                    Similar Stocks
                    Price & Change
                    Brickell Biotech
                    Merck & Company

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis